Owing to the fact that the clinical efficacy of AUY922 remains poor in monotherapies, it has been synergized with trametinib in KRAS-mutant NSCLC and represented a potent anti-tumor activity both in vitro and in vivo [186]. Here, KRAS is linked to non-small cell lung carcinoma.